ARS PHARMACEUTICALS ($SPRY) posted quarterly earnings results for Q1 2026 on Friday, May 15th. The company reported earnings of -$0.61 per share, missing estimates of -$0.51 by $0.10. The company also reported revenue of $22,680,000, missing estimates of $22,753,282 by $-73,282.
You can see Quiver Quantitative's $SPRY stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
ARS PHARMACEUTICALS Hedge Fund Activity
We have seen 86 institutional investors add shares of ARS PHARMACEUTICALS stock to their portfolio, and 99 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- MILLENNIUM MANAGEMENT LLC added 3,168,406 shares (+inf%) to their portfolio in Q4 2025, for an estimated $36,911,929
- ALLIANCEBERNSTEIN L.P. removed 2,581,991 shares (-97.7%) from their portfolio in Q4 2025, for an estimated $30,080,195
- RUBRIC CAPITAL MANAGEMENT LP added 1,700,000 shares (+37.8%) to their portfolio in Q4 2025, for an estimated $19,805,000
- MPM BIOIMPACT LLC removed 1,303,399 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $15,184,598
- QUBE RESEARCH & TECHNOLOGIES LTD removed 1,034,798 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $12,055,396
- TYRO CAPITAL MANAGEMENT LLC added 973,747 shares (+48.8%) to their portfolio in Q1 2026, for an estimated $7,819,188
- FIL LTD added 810,073 shares (+inf%) to their portfolio in Q4 2025, for an estimated $9,437,350
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
Check out the Quiver Quantitative API to build on top of data on congressional stock trading, insider transactions, hedge fund moves, and more.
